Followers | 18 |
Posts | 932 |
Boards Moderated | 0 |
Alias Born | 04/26/2016 |
Wednesday, July 19, 2017 6:05:27 PM
Aurora Trial update:
-Phase 3 has commenced and off to a strong start having 26 trial sites already enrolling patients, and expected to have upwards of 200 sites total for a full enrollment of around 320 patients.
-This is a fully blinded study, with no interim data. Enrollment is expected to take 12-18 months, and top-line data is expected following the 52wk period of the last patient enrolled.
Any other catalysts in the meantime?
-CEO Dr. Glickman has informed everyone that they plan to announce this fall their plans of seeking additional indications for VoC.
-VoC has been studied in over 2600 patients for various conditions and indications. VoC has performed very well in a few of those trials. For various reasons when AUPH was formed they decided LN was the best opportunity for their first approval.
-Glickman confirmed they will be seeking multiple additional indications, with Dre Eye Sydrome (DES) being one of them. Out of the conditions they've already studied I would anticipate either Transplant or Psoriasis will be another indication they will pursue.
-AUPH has already been approved for a Ph3 transplant study with SPA (Special Protocol Assessment).
-VoC is a more efficient & less toxic Cyclosporine, so anything Cyclosporine has been used for is potentially a target.
-There is always the possibility that they have other autoimmune diseases in mind that they haven't already pursued in the past.
The future is bright, but can AUPH handle all that?:
-Auph has $200m on hand to get them to approval for LN. These other indications will cost a lot and additional funding will be needed. I believe it's very likely we see a partnership in the near future.
-Auph is in a great position for negotiating a partnership, so I expect the terms to be very favorable. If they announce a partnership at the same time as the new indications (which I hope they do), skies the limit!
-Auph has the attention of many types of players (tutes, longs, shorts, traders, options, etc.) so guessing the day-to-day & week-to-week action doesn’t interest me much. I've been long for well over a year and will hold for the endgame while not paying too much attention to the rollercoaster ride along the way.
VoC's History:
-Voclosporin Development History
Voclosporin has been tested in more than 2,600 patients, including studies where it was compared to placebo or active control. The safety
and tolerability profile of the drug therefore is well characterized. Phase 2 or later clinical studies that have been completed include studies
in the following indications:
Psoriasis: To date, two Phase 3 clinical studies in patients with moderate to severe psoriasis have been completed. The primary efficacy
endpoint in both studies was a reduction in Psoriasis Area and Severity Index, which is a common measure of psoriasis disease severity.
The first study treatment with voclosporin resulted in statistically significantly greater success rates than treatment with placebo by the
twelfth week. In a second study comparing voclosporin against cyclosporine, the drug was not shown to be statistically non-inferior to
cyclosporine in terms of efficacy; however, voclosporin proved superior in terms of limiting elevations in hyperlipidemia. Due to the
evolving psoriasis market dynamics and the changing standard of care for the treatment of this disease the Company has decided not to
pursue further Phase 3 development.
Renal Transplantation: A Phase 2b clinical trial in de novo renal transplant recipients was completed. Study ISA05-01, the PROMISE
Study was a six month study with a six month extension comparing voclosporin directly against tacrolimus on a background of MMF and
corticosteroids. Voclosporin was shown to be equivalent in efficacy, but superior to tacrolimus with respect to the incidence of new onset
diabetes after transplantation. In 2010, tacrolimus lost its exclusivity in most world markets and as a result, the competitive pricing
environment for voclosporin for this indication has come into question. Additionally, the more expensive development timelines for this
indication has made it a less attractive business proposition as compared to the LN indication, even when considering the fact that a special protocol assessment has been agreed to by the FDA for this indication.
Uveitis: Multiple studies in various forms of non-infectious uveitis have been completed over the past several years by Lux, a former
licensee of the Company, indicating mixed efficacy. In all but one of the studies, completed by the licensee, an impact on disease activity
was shown in the voclosporin group. However achievement of the primary end-points in multiple studies could not be shown. Uveitis is a
notoriously difficult disease to study due to the heterogeneity of the patient population and the lack of validated clinical end-points.
However in all of the uveitis studies completed, the safety results were consistent and the drug was well tolerated. The Company has now
successfully terminated its licensing agreement with Lux. In conjunction with this termination the Company has retained a portfolio of
additional patents that Lux had been prosecuting that are focused on delivering effective concentrations of voclosporin to various ocular
tissues. The Company will continue to evaluate these patents and make strategic recommendations on how they fit into the ongoing
strategic directives of the Company.
Good luck to all, and please remember this is my opinion only
Recent AUPH News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/20/2024 08:56:55 PM
- Aurinia to Participate in 2024 Cantor Fitzgerald Global Healthcare Conference • Business Wire • 09/13/2024 10:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/12/2024 08:08:25 PM
- Aurinia Announces Board Restructuring • Business Wire • 09/12/2024 08:05:00 PM
- Aurinia Announces First Participant Dosed in AUR200 Single Ascending Dose Trial • Business Wire • 09/05/2024 10:00:00 AM
- Aurinia to Participate in H.C. Wainwright 26th Annual Global Investment Conference • Business Wire • 08/28/2024 10:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/08/2024 08:06:59 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/01/2024 10:07:59 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 10:03:38 AM
- Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2024 Financial and Operational Results • Business Wire • 08/01/2024 10:00:00 AM
- Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 1, 2024 • Business Wire • 07/19/2024 10:00:00 AM
- Aurinia to Participate in Upcoming Investor Healthcare Conferences • Business Wire • 07/02/2024 10:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 09:25:28 PM
- Aurinia Announces 2024 Annual General Meeting Results • Business Wire • 06/14/2024 04:16:00 PM
- Aurinia Presents Safety and Efficacy Profile of LUPKYNIS® for People with Lupus Nephritis at European Alliance of Associations for Rheumatology (EULAR) Congress 2024 • Business Wire • 06/05/2024 10:00:00 AM
- Aurinia Addresses Dubious Proposals Put Forth by Lucien Selce • Business Wire • 06/04/2024 09:30:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 06/04/2024 09:25:39 PM
- Aurinia Provides Update on Proxy Statement • Business Wire • 06/03/2024 10:30:00 PM
- Aurinia Will Attend 2024 Jefferies Global Healthcare Conference • Business Wire • 05/30/2024 10:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:16:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:14:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:11:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:09:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:07:15 PM
- Analysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation’s Spring Clinical Meeting 2024 • Business Wire • 05/14/2024 10:00:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM